Shots:

• F-star to receive a $1M up front license fee & will be also eligible to receive ~$40M upon the achievement of milestones along with royalties on annual net sales
• Under the terms of the agreement, Takeda gets an exclusive royalty-bearing license globally to research, develop, and commercialize a bispecific Ab against an immuno-oncology target for the treatment of cancer by using F-star’s Fcab and mAb2 platforms & will lead the research, development, and commercialization activities
• The collaboration will use Fcab technology to diversify and accelerate Takeda’s gamma delta (γδ) T cell engager portfolio to develop therapies for cancer patients

Ref: GlobalNewswire | Image: Takeda